fda compounding glp-1 warning letters october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Issues Warning Letter to

29, 2024 from Aetna-b

A clinician should review your full list of medications, dose timing, and recent blood sugar trends

More than 13 million Medicare beneficiaries met the BMI thresholds for obesity or overweight in 2023, but not all are potentially eligible for the Medicare GLP-1 Bridge

Besides the primary injury, the subsequent secondary injury caused by inflammation, edema, free radical peroxidation, local circulatory disorder, abnormal energy metabolism, electrolyte disorder, programmed apoptosis, nitric oxide and endogenous opioid peptides, and accumulation of excitatory neurotransmitters further exacerbate the damage to the spinal cord tissue (Rogers and Todd, 2016)

These groups were evaluated on how the effect of GLP-1 had on apoptosis